Statement by Vigmed’s bid committee in relation to the extended acceptance period to the public offer by Greiner Bio-One
The independent Vigmed Bid Committee continues to recommend the shareholders to accept the Greiner Bio-One Offer.On 27 February 2017, Greiner Bio-One GmbH (“GBO”) announced a public cash offer to the shareholders of Vigmed Holding AB (publ) (“Vigmed”) at the price of SEK 1.00 in cash per share (the “Offer”). The shares tendered in the Offer at the end of the initial acceptance period on 27 March 2017 amounted to a total of 42,709,627 shares in Vigmed, corresponding to approximately 65 percent of total outstanding shares and votes in Vigmed. In view of the completion of the Offer being